Key takeaways
Incruse Ellipta (umeclidinium) and Breo Ellipta (fluticasone/vilanterol) are both inhalers used for the maintenance treatment of chronic obstructive pulmonary disease (COPD), but they have some key differences. Incruse Ellipta is a long-acting muscarinic antagonist (LAMA) that works by relaxing the muscles in your airways. Breo Ellipta, on the other hand, combines an inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA) to reduce inflammation and relax airway muscles. Incruse Ellipta is only available as a brand-name medication, whereas Breo Ellipta has a lower-cost generic option. Incruse Ellipta is not approved for asthma, but Breo Ellipta is approved for both COPD and asthma in adults and children. Common side effects of Incruse Ellipta include cold symptoms and cough, while Breo Ellipta can cause upper respiratory infections, sore throat, and headache. Additionally, Breo Ellipta requires you to rinse your mouth after use to prevent fungal infections, a step not needed with Incruse Ellipta.
